Integra Lifesciences Holdings Corp (NASDAQ:IART) has received an average rating of “Hold” from the fourteen ratings firms that are currently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and five have given a buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $58.64.
A number of brokerages have weighed in on IART. Zacks Investment Research upgraded Hanmi Financial from a “sell” rating to a “hold” rating in a report on Thursday, June 20th. ValuEngine lowered Acceleron Pharma from a “strong-buy” rating to a “buy” rating in a report on Thursday, April 18th. Oppenheimer raised their price objective on Chipotle Mexican Grill from $400.00 to $525.00 and gave the company an “underperform” rating in a report on Thursday, April 25th. Finally, BidaskClub lowered Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, July 9th.
Integra Lifesciences stock traded up $0.78 during trading on Friday, reaching $54.07. The company had a trading volume of 11,584 shares, compared to its average volume of 445,465. The company has a 50-day moving average of $51.93. Integra Lifesciences has a 1-year low of $42.14 and a 1-year high of $66.41. The company has a market capitalization of $4.60 billion, a price-to-earnings ratio of 22.32, a PEG ratio of 1.62 and a beta of 1.07. The company has a debt-to-equity ratio of 0.95, a current ratio of 2.86 and a quick ratio of 1.86.
Integra Lifesciences (NASDAQ:IART) last released its quarterly earnings results on Wednesday, April 24th. The life sciences company reported $0.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.61 by $0.04. Integra Lifesciences had a net margin of 5.60% and a return on equity of 15.60%. The firm had revenue of $359.69 million for the quarter, compared to analysts’ expectations of $361.12 million. During the same quarter last year, the company earned $0.58 EPS. The firm’s revenue for the quarter was up .7% compared to the same quarter last year. As a group, analysts expect that Integra Lifesciences will post 2.7 EPS for the current fiscal year.
In other news, COO Glenn Coleman sold 3,650 shares of Integra Lifesciences stock in a transaction on Friday, June 28th. The stock was sold at an average price of $55.00, for a total transaction of $200,750.00. Following the transaction, the chief operating officer now owns 25,160 shares in the company, valued at approximately $1,383,800. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Christian S. Schade sold 15,658 shares of Integra Lifesciences stock in a transaction on Friday, May 10th. The stock was sold at an average price of $51.56, for a total value of $807,326.48. The disclosure for this sale can be found here. Company insiders own 4.50% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Fort L.P. purchased a new stake in Integra Lifesciences in the 4th quarter valued at about $34,000. Quadrant Capital Group LLC grew its position in Integra Lifesciences by 223.0% in the 1st quarter. Quadrant Capital Group LLC now owns 646 shares of the life sciences company’s stock valued at $34,000 after acquiring an additional 446 shares in the last quarter. Executive Wealth Management LLC acquired a new position in Integra Lifesciences in the 4th quarter valued at about $38,000. Captrust Financial Advisors grew its position in Integra Lifesciences by 43.6% in the 4th quarter. Captrust Financial Advisors now owns 2,330 shares of the life sciences company’s stock valued at $105,000 after acquiring an additional 707 shares in the last quarter. Finally, NumerixS Investment Technologies Inc grew its position in Integra Lifesciences by 100.1% in the 4th quarter. NumerixS Investment Technologies Inc now owns 2,801 shares of the life sciences company’s stock valued at $124,000 after acquiring an additional 1,401 shares in the last quarter. Institutional investors and hedge funds own 82.27% of the company’s stock.
Integra Lifesciences Company Profile
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.
Recommended Story: Gap Down Stocks
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.